# US 2013/0158273 A1 · Preparation of bendamustine and its salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158273 A1
- Document ID: US20130158273A1
- Status: Published application
- Kind: A1
- Application number: 13/517,908
- Filed: 2010-12-22
- Published: 2013-06-20
- Earliest claimed: 2009-12-23
- Assignees: Dr. Reddy's Laboratories, Inc.
- Inventors: Rajasekhar Kadaboina; Veerender Murki; Venkat Rao Badisa; Nageshwar Gunda
- Web page: https://patentgrep.com/patent/US20130158273A1

## CPC

- C07D 235/16: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 35/02: specific for leukemia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relate to processes for the preparation of bendamustine and its pharmaceutically acceptable salts.

## Claims

### Claim 1

A process comprising:
a) reacting a compound of formula (II):
wherein R is a C1-C4 alkyl group, with a 2-haloethanol in the presence of an organic base to give a compound of formula (III);
b) reacting the compound of formula (III) with a chlorinating agent to provide a compound of formula (IV); and
c) hydrolyzing the compound of formula (IV) to give bendamustine hydrochloride.

### Claim 2 (depends on 1)

The process of claim 1, wherein the 2-haloethanol consists of 2-chloroethanol, 2-bromoethanol, or 2-iodoethanol.

### Claim 3 (depends on 1)

The process of claim 1, wherein the organic base consists of triethylamine, diisopropyl amine, diisopropyl-ethylamine, DABCO, pyridine, lutidine, 4-dimethylaminopyridine, or 4-methylmorpholine.

### Claim 4 (depends on 1)

The process of claim 1, wherein the organic base consists of triethylamine, diisopropyl amine, or diisopropyl-ethylamine.

### Claim 5 (depends on 1)

The process of claim 1, wherein the chlorinating agent used in step b) consists of sulphuryl chloride, thionyl chloride, phosphorous trichloride, phosphorous pentachloride, or phosphorous oxychloride.

### Claim 6 (depends on 1)

The process of claim 1, wherein step b) is carried out in the presence of a halogenated hydrocarbon solvent.

### Claim 7 (depends on 1)

The process of claim 1, where in step b) consists of:
a) reacting the compound of formula (Ill) with a chlorinating agent in the presence of a halogenated hydrocarbon solvent;
b) adding water;
c) separating the organic layer, optionally concentrating to a minimum volume;
d) adding an anti-solvent selected from a C5-C8 alkane, such as pentane, hexane, or heptane; and
e) isolating the compound of formula (IV) as a solid.

### Claim 8 (depends on 1)

The process of claim 1, wherein step c) is carried out using aqueous hydrochloric acid.

### Claim 9 (depends on 1)

The process of claim 1, wherein step c) is carried out using aqueous hydrochloric acid having concentration from about 0.5 N to about 5 N.

### Claim 10 (depends on 1)

The process of claim 1, wherein step c) is carried out using aqueous hydrochloric acid and at temperatures less than about 60° C.

### Claim 11

A process for the purification of bendamustine hydrochloride, comprising:
a) combining bendamustine hydrochloride, aqueous hydrochloric acid, and acetonitrile;
b) heating the mixture of step a) to a temperature from about 35° C. to about 65° C.;
c) cooling the mixture of step b) to a temperature from about 0° C. to about 35° C.; and
d) isolating bendamustine hydrochloride.

### Claim 12 (depends on 11)

The process of claim 11, wherein aqueous hydrochloric acid having concentrations of from about 0.1 N to about 5 N is used in step a).

### Claim 13 (depends on 11)

The process of claim 11, wherein the bendamustine hydrochloride obtained in step d) is characterized by powder X-ray powder diffraction pattern as depicted in FIG. 3.

### Claim 14

A compound of the formula (IIIa):

### Claim 15

A process for the preparation of bendamustine hydrochloride, comprising subjecting the compound of the formula (IIIa) to suitable reaction conditions

### Claim 16

A compound of the formula (IIa):

### Claim 17

A process for the preparation of bendamustine hydrochloride, comprising subjecting the compound of the formula (IIa) to suitable reaction conditions

### Claim 18

A compound of the formula (IVa):

### Claim 19

A process for the preparation of bendamustine hydrochloride, comprising subjecting the compound of the formula (IVa) to suitable reaction conditions

### Claim 20

Bendamustine hydrochloride having purity greater than 99.8% and with less than about 0.1% of each of the compound given in the table below:
Code
Structure
HP1
HP2
Impurity A
Impurity B′
Formula IV
wherein R is C1-C4alkyl.
